274 related articles for article (PubMed ID: 16209659)
1. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
3. Moxonidine: a new antiadrenergic antihypertensive agent.
Prichard BN; Graham BR; Owens CW
J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
[TBL] [Abstract][Full Text] [Related]
4. Biphasic dose-dependent modulation of cardiac parasympathetic activity by moxonidine, an imidazoline I1-receptor agonist.
Turcani M
J Cardiovasc Pharmacol; 2008 Dec; 52(6):524-35. PubMed ID: 19034032
[TBL] [Abstract][Full Text] [Related]
5. Effective antihypertensive therapy: blood pressure control with moxonidine.
Prichard BN; Graham BR
J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
[TBL] [Abstract][Full Text] [Related]
6. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of moxonidine on cardiac autonomic modulation.
Kaya D; Barutcu I; Esen AM; Celik A; Onrat E
Pacing Clin Electrophysiol; 2010 Aug; 33(8):929-33. PubMed ID: 20230461
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular effects of imidazoline receptor activation in heart failure.
Stabile AM; Aceros H; Stockmeyer K; Abdel Rahman AA; Noiseux N; Mukaddam-Daher S
Life Sci; 2011 Mar; 88(11-12):493-503. PubMed ID: 21277868
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of I(1)-antihypertensive agent moxonidine against neurogenic cardiac arrhythmias in halothane-anesthetized rabbits.
Poisson D; Christen MO; Sannajust F
J Pharmacol Exp Ther; 2000 Jun; 293(3):929-38. PubMed ID: 10869394
[TBL] [Abstract][Full Text] [Related]
10. Thoracic epidural anesthesia during coronary artery bypass surgery: effects on cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics.
Kirnö K; Friberg P; Grzegorczyk A; Milocco I; Ricksten SE; Lundin S
Anesth Analg; 1994 Dec; 79(6):1075-81. PubMed ID: 7978429
[TBL] [Abstract][Full Text] [Related]
11. Evidence that some imidazoline derivatives inhibit peripherally the vasopressor sympathetic outflow in pithed rats.
Monroy-Ordoñez EB; Villalón CM; Cobos-Puc LE; Márquez-Conde JA; Sánchez-López A; Centurión D
Auton Neurosci; 2008 Dec; 143(1-2):40-5. PubMed ID: 18774761
[TBL] [Abstract][Full Text] [Related]
12. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
[TBL] [Abstract][Full Text] [Related]
14. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
[TBL] [Abstract][Full Text] [Related]
15. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
[TBL] [Abstract][Full Text] [Related]
16. The renaissance of centrally acting antihypertensive drugs.
van Zwieten PA
J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of moxonidine on ischemia/reperfusion-induced acute kidney injury through α2/imidazoline I1 receptor.
Tsutsui H; Sugiura T; Hayashi K; Yukimura T; Ohkita M; Takaoka M; Matsumura Y
Eur J Pharmacol; 2013 Oct; 718(1-3):173-80. PubMed ID: 24041924
[TBL] [Abstract][Full Text] [Related]
18. The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidine.
Penner SB; Smyth DD
Br J Pharmacol; 1995 Nov; 116(6):2631-6. PubMed ID: 8590981
[TBL] [Abstract][Full Text] [Related]
19. Imidazoline receptors but not alpha 2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment.
El-Ayoubi R; Menaouar A; Gutkowska J; Mukaddam-Daher S
J Pharmacol Exp Ther; 2004 Aug; 310(2):446-51. PubMed ID: 15075383
[TBL] [Abstract][Full Text] [Related]
20. Contrasting metabolic effects of antihypertensive agents.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Dec; 307(3):1104-11. PubMed ID: 14557373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
